Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Soligenix, a late-stage biotechnology company, has received European patent EP 1830857 ‘Method of Treatment of Graft-versus-Host Disease and Leukemia with Beclomethasone Dipropionate and Prednisone.’
Subscribe to our email newsletter
The patent claims beclomethasone dipropionate (BDP) in conjunction with a short duration of high-dose prednisone with a rapid taper for the reduction of mortality associated with Graft-versus-Host disease (GVHD) and leukemia.
Soligenix claimed that the oral BDP has the potential to provide a safer and more efficacious method to treat GVHD than prolonged treatment with high-dose systemic glucocorticoids.
This is the second European patent granted to Soligenix this year concerning its BDP technology, an active ingredient in orBec, a proprietary oral formulation for treatment of acute gastrointestinal (GI) GVHD.
In addition to issued patents and pending worldwide patent applications held by or exclusively licensed to Soligenix, orBec also benefits from orphan drug designations in the US and in Europe for the treatment of GI GVHD, which provide for seven and 10 years of post-approval market exclusivity, respectively.
Christopher Schaber, president and CEO of Soligenix, said: “This patent is based on evidence that we have generated in a previous Phase 3 GVHD clinical trial that orBec significantly reduces mortality.
“This patent further solidifies our proprietary position in the field of topically active steroids and is yet another building block in our growing intellectual property estate for oral BDP. We are pleased that our work in the field of topically active steroids and GVHD is now materialising into a robust portfolio of issued patents.”